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Abstract: Naringin (NRG) is a flavanone glycoside present in grapefruit juice. Its biological activity has been only partially characterized 
and little is known about its potential effects in the cardiovascular system. We studied the effects of NRG on the electrical and contractile 
activities of isolated rat hearts and on the contraction of rat abdominal aortic rings. NRG exerted a negative inotropic action in hearts with an 
IC50 of 72.5 µmol/L but its effects on heart rate and surface electrogram were minimal. Surprisingly, NRG (10-100 µmol/L) was able to 
increase tension in aortic rings contracted by isotonic KCl or phenylephrine. This action of NRG was also evident in aortic rings in basal 
(resting) conditions but it was absent when resting aortic rings were previously perfused with ryanodine (30 µmol/L). Our results indicate 
that NRG has direct actions on cardiac and vascular smooth muscles that should be taken into account when considering this molecule either 
as a dietetic supplement or as a template to develop therapeutic agents for human diseases. 
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Resumen: La naringina (NRG) es un glicósido de flavanona que se encuentra presente en el jugo de toronja. Su actividad biológica ha sido 
solo parcialmente caracterizada y poco se conoce acerca de sus efectos sobre el sistema cardiovascular. En la presente investigación 
estudiamos los efectos de la NRG sobre las actividades eléctrica y contráctil de corazones aislados de rata y sobre la contracción de anillos 
de aorta abdominal de rata. La NRG ejerció una acción inotropo-negativa en corazones con una IC50 de 72.5 µmol/L pero sus efectos sobre 
la frecuencia cardíaca y el electrograma de superficie fueron mínimos. Sorpresivamente, la NRG (10-100 µmol/L) incrementó la tensión en 
anillos de aorta contraídos por KCl isotónico o fenilefrina. Esta acción de la NRG ocurrió también en anillos de aorta en condiciones basales 
(en reposo) pero estuvo ausente cuando los anillos de aorta fueron previamente perfundidos con ryanodina (30 µmol/L). Nuestros resultados 
indican que la NRG tiene acciones directas sobre los músculos cardíaco y liso vascular que deben tenerse en cuenta al considerar esta 
molécula como suplemento dietético o como plantilla para el desarrollo de agentes terapéuticos para el tratamiento de enfermedades en 
humanos. 
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Note 
On July the 29
th
, 2013 Dr Francisco José Morón Rodríguez died suddenly. As a medical doctor and Second Degree 
Specialist in Pharmacology, Dr Morón had a fruitful career as a professor and researcher in the “Dr. Salvador 
Allende” Faculty of Medicine. He was member of the Cuban Society of Pharmacology and founder director of the 
Revista Cubana de Plantas Medicinales. He was member of the Editorial Advisory Board of the Boletín 
Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas (BLACPMA). Due to his competence, 
solidarity, modesty and dedication to work, he was an example of health professional. He stood out for its support 
to the research on therapeutic agents obtained from plants. At the time of his death, he was the Director of the 
Central Laboratory of Pharmacology of the “Dr. Salvador Allende” Faculty of Medical Sciences of the Havana 
University of Medical Sciences. 
 
Nota 
El 29 de julio de 2013 falleció súbitamente el Dr Francisco José Morón Rodríguez. Como médico y especialista de 
Segundo Grado en Farmacología, el Dr. Morón tuvo una fecunda trayectoria como profesor e investigador en la 
Facultad de Ciencias Médicas “Dr. Salvador Allende”. Era miembro de la Sociedad Cubana de Farmacología y 
director fundador de la Revista Cubana de Plantas Medicinales. Era miembro del Consejo Editorial del Boletín 
Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas (BLACPMA). Por su capacidad, modestia, 
solidaridad y entrega al trabajo, fue ejemplo de profesional de la salud. Se destacó por el impulso a las 
investigaciones y aplicación de agentes terapéuticos obtenidos de plantas medicinales. Al momento de su 
fallecimiento ocupaba el cargo de Director del Laboratorio Central de Farmacología de la Facultad de Ciencias 
Médicas “Dr. Salvador Allende” de la Universidad de Ciencias Médicas de la Habana. 
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INTRODUCTION 
Flavonoids constitute a complex chemical group of 
natural compounds comprising the flavanols, 
flavanones, flavones, isoflavones, flavonols, 
anthocyanidin and proanthocyanidin subgroups 
(McNaught and Wilkinson, 1997). Early in the nineties 
epidemiological studies showed that an association 
seemed to exist between dietary intake of flavonoids 
and the reduction of myocardial infarction and stroke 
in some populations (Hertog et al., 1993; Keli et al., 
1996). Since then, evidence arose suggesting that 
flavonoids could have a potential therapeutic value in 
the prevention and treatment of cardiovascular 
diseases (Benavente-García and Castillo, 2008; 
Habauzit and Morand, 2012). Several clinical trials 
have been conducted to explore the possible beneficial 
effects of flavonoids intake. Most results are 
suggestive of a reduced cardiovascular risk in 
individuals having flavonoid-rich diets. The beneficial 
effects of flavonoids have been usually associated to 
their anti-oxidant, anti-inflammatory, anti-proliferative 
and anti-thrombotic actions (see for review Wright et 
al., 2013). However, intracellular modulator actions of 
flavonoids could be quite diverse and complex (Wright 
et al., 2013). In addition, as pointed out by Wrigth and 
co-workers physiological and pharmacological actions 
of flavonoids can be affected by sex, lifestyle, disease 
states and interactions with drugs thus limiting their 
impact on human health (see also Chanet et al., 2012). 
Nevertheless, these compounds are extremely 
interesting as molecular templates to design drugs with 
better pharmacological profiles for the treatment of 
human cardiovascular diseases. 
 The flavanone naringin is the major flavonoid 
in grapefruit juice (Peterson et al., 2006; Rouseff 
1988), an important dietary source of flavonoids, and 
for this reason studies have been conducted to study 
the pharmacological actions of naringin and its 
aglycone naringenin. Naringin was reported as being 
effective in protecting against bone loss in 
ovariectomised mice, an effect that is probably 
mediated through ligand-independent activation of 
œstrogen receptor in osteoblastic cells (Pang et al., 
2010). Moreover, naringin can improve bone quality in 
senescent rats (Habauzit et al., 2011). Its antioxidant 
action could be responsible, at least in part, for its 
neuroprotective effect in human dopaminergic cells 
SH-SY5Y (Choi et al., 2010) and PC12 cells (Lu et 
al., 2010), for its blockade of the proinflammatory 
effect of interferon-γ and histamin in human 
keratinocytes (Cardile et al., 2010; Graziano et al., 
2012) and for its anti-inflamatory action in the rat air 
pouch model of inflammation (Jain and Parmar, 2011). 
Interestingly, naringin but not its aglycone naringenin 
had a CNS depressing action in mice suggesting that 
the sugar moiety could be important for this action 
following systemic administration of the flavonoid 
(Fernández et al., 2006). It has also been reported that 
naringin (and other flavonoids) possess hypouricemic 
action in mice, an effect that seems to be related to the 
inhibition of liver xanthyne oxidase activity (Mo et al., 
2007), and reduces radiation-induced damage to DNA 
(Jagetia et al., 2003). In addition, naringin decreases 
the release of the angiogenic vascular endothelial 
growth factor (Schindler and Mentlein, 2006) and 
protects against ethanol injury in rats (Martin et al., 
1994). It could also decrease total cholesterol levels 
(da Silva et al., 2001; Lee et al., 2001; Ueng et al., 
1999) and possesses anti-apoptotic properties (Gordon 
et al., 1995). 
 Naringin also seems to have a cardioprotective 
action in isoproterenol-induced myocardial infarction 
in rats (Rajadurai and Prince, 2007a; Rajadurai and 
Prince, 2007b). Although the mechanism of 
cardioprotection was no elucidated, it seems to involve 
complex pathways. In stroke-prone spontaneously 
hypertensive rats, orally-administered naringin (as 
well as hesperidin and glucosyl-hesperidin) was 
reported to suppress the age related increase in blood 
pressure, to significantly decrease thrombotic tendency 
and to increase nitric oxide (NO) production thus 
improving vasodilation induced by an acetylcholine-
mediated NO production in the endothelium (Ikemura 
et al., 2012). These results could explain in part its 
beneficial effect on the mechanisms of hypertension 
and thrombosis. However, most probably the effects 
were due to the actions of naringenin, the aglycone 
formed during the cleavage of the sugar moiety of 
naringin after its ingestion (Fuhr and Kummert, 1995). 
It should be noted here that the aglycone naringenin 
was among the less efficient flavonoids in releasing 
NO in porcine coronary arteries (Taubert et al., 2002). 
In a recent report it was suggested that naringin could 
inhibit high glucose-induced apoptosis by attenuating 
mitochondrial dysfunction and modulating the 
activation of the p38 signaling pathway (Huang et al., 
2013). However, little is known about the possible 
direct cardiovascular physiological actions of naringin. 
Saponara et al. (2006) reported that naringin and its 
aglycone naringenin could increase the conductance of 
vascular smooth muscle calcium-activated potassium 
ion channels (BK(Ca)); naringin showed, however, a 
poor vasorelaxing action in rat aortic rings compared 
to naringenin a fact that could be linked to its 
Lopez-Medina et al. Cardiovascular actions of naringin 
 
 
Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas/241 
 
glycoside moeity (Saponara et al., 2006). Naringenin 
also blocks the cardiac hERG channels (Scholz et al., 
2005; Zitron et al., 2005). In one report, the effects 
naringin were studied on recombinant human KIR3.1–
3.4 and KIR3.1–3.2 expressed in Xenopus oocytes 
using the two-electrode voltage clamp method (Yow et 
al., 2011; see also Oki et al., 2012 in HAC15 cells). 
The results indicated that naringin (but not its 
aglycone naringenin) is a direct activator of inward 
rectifying K currents, an effect that could have an 
impact on heart rate at least in isolated heart or 
spontaneous activity in single cell preparations. 
 The aim of the present investigation was to 
characterize the possible direct actions of naringin on 
electrical and contractile activities of rat isolated 
hearts and on the contraction of endothelium-deprived 
rat aortic rings. 
 
MATERIALS AND METHODS 
Naringin extraction and purification 
Naringin was obtained according to the method of 
Ikan (Ikan, 1991). In brief, naringin was extracted in 
hot water from the grapefruit (Citrus maxima (Burm.) 
Merrill) peel along with a small quantity of pectin. The 
extract was concentrated to ~1/9 of the original 
volume yielding naringin as an octahydrate. 
Recrystallization from isopropanol gave the pure 
dihydrate. Both purified and commercial naringin 
(Sigma, USA; kindly provided by Prof K. Talavera; 
Leuven) were dissolved in ethanol:water (1:1) at 0.2 
mmol/L and subjected to reversed-phase C18 HPLC in 
an Ultropac Spherisorb ODS2 column (3 µm particle 
size, 100 × 4.6 mm i.d.). Separations were performed 
at 1 mL/min employing an increasing linear gradient 
of acetonitrile from 85/5/10 to 45/45/10 (%A/%B/%C) 
in 40 min, being A: water, B: acetonitrile and C: 0.1% 
ortho-phosphoric acid in water. The eluting 
compounds were online detected by UV absorption at 
254 nm. The separation was carried out on a Knauer 
HPLC system (Knauer, Germany). 
 
Isolated hearts 
Experiments were performed on male adult Wistar rats 
according to the guidelines of the National Center for 
Laboratory Animal Reproduction (CENPALAB). As 
previously reported (Galán et al., 1998), under 
pentobarbital anaesthesia hearts were removed and 
placed in cold Tyrode (see below). They were 
carefully dissected, mounted on a Langendorff column 
and perfused at constant flow (10 mL/min) with a 
Tyrode solution of the following composition 
(mmol/L): NaCl 140; KCl 2.5; MgCl2 0.5; CaCl2 2; 
Tris-hydroxymethylaminomethane 10; Glucose 5 (pH 
= 7.4, gassed with O2; T = 35° C). A bipolar platinum 
recording electrode was placed on the right ventricular 
epicardium and the surface electrocardiogram (ECG) 
was recorded with a biophysical amplifier (AVB-10; 
Nihon Kohden, Japan). Another bipolar platinum 
electrode was placed near the atrioventricular ring and 
was connected to an electronic stimulator (SEN-7103; 
Nihon Kohden, Japan) through a stimulus-isolating 
unit (SS-102J; Nihon Kohden, Japan). Cardiac apex 
was fixed to a force-displacement transducer (SB-1T; 
Nihon Kohden, Japan) with a surgical 5-0 or 6-0 silk 
thread. The force of contraction (FC) was recorded 
using a low-level DC preamplifier (ACH-8; Nihon 
Kohden, Japan). Analogue signals (ECG and FC) were 
digitized (100 μs sampling interval) using an AD/DA 
converter (Labmaster TL-1-125, Mentor, Ohio, USA), 
stored on a computer and analyzed off-line with the 
ACQUIS1 (version 2.0, CNRS License, France) and 
SciDAVis (Debian GNU/Linux; version 0.2.4) 
softwares. ECG and FC values were recorded at the 
spontaneous heart rate and at a fixed stimulus rate 
(200 bpm). Hearts were let to stabilize for at least 30 
min before beginning the experiments. 
 
Aortic rings 
Abdominal aortic rings were dissected from rats under 
pentobarbital anaesthesia. Care was taken to 
mechanically remove the endothelium. They were 
fixed to a force transducer and placed in bath chamber 
continuously perfused (10 mL/min) with the same 
Tyrode solution used for isolated hearts (pH = 7.4, 
gassed with O2; T = 35° C) and stabilized, under a load 
of 0.5 g, for 30 min before the beginning of the 
experiment. Contraction was induced by replacing all 
NaCl by KCI (140 mmol/L) or by phenylephrine (PE) 
10 µmol/L (Galán et al., 1998). 
Nifedipine (Sigma, USA; kindly provided by 
Prof G. Vassort; Montpellier) was prepared as a stock 
solution (10 mmol/L) in ethanol and was used as 
reference compound. Results were analyzed using a 
Student's t-test for paired or unpaired samples as 
required using the Gnumeric Spreadsheet (Gnome 
Project, version 1.10.17). Differences were considered 
statistically significant for p < 0.05. Results are 
expressed as Means ± Standard Errors of Means. 
 
RESULTS 
Extracted and purified naringin 
The obtained naringin was analyzed by RP18-HPLC. 
The resulting chromatographic profile (Figure 1A) 
yielded a very dominant, narrow and symmetric peak 
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that eluted at 17.50 min, indicating the high purity of 
the compound. Moreover, its retention time exactly 
matched the behaviour of commercial naringin (Figure 
1B), confirming the presence of naringin in the 
purified sample. Only extracted and purified naringin 
(NRG) was used for the pharmacological experiments. 
 
Figure 1 
 
Extracted naringin is of high purity. Reversed-phase C18 chromatographic profiles of naringin obtained as 
reported in Methods (A) and commercial naringin (B). Both chromatographic separations were performed in 
identical conditions. Column: Ultropac Spherisorb ODS2 (3 µm particle size, 100 × 4.6 mm i.d.), flow rate: 1 
mL/min, gradient program: 85/5/10 to 45/45/10 (%A/%B/%C) in 40 min, being A: water, B: acetonitrile and C: 
0.1% ortho-phosphoric acid in water. Sample volume: 100 µL. 
 
Effects on cardiac electrical and mechanical 
activities. 
NRG, in the concentration range from 1 to 100 
µmol/L, barely affected spontaneous electrical activity 
of isolated rat hearts (n = 9 hearts). NRG changed 
neither QRS duration nor its amplitude. RR interval 
was also not significantly changed by NRG within this 
concentration range. Corrected QT (QTc = QT/√RR) 
was not significantly affected by NRG at 
concentrations from 1 to 10 µmol/L. However, at 30 
and 100 µmol/L concentrations, NRG showed a 
tendency to decrease QTc (from 9.4 ± 1 ms in control 
to 7.1 ± 1 ms and 7.0 ± 2 ms, respectively) but without 
statistical significance. On the other hand, NRG 
significantly decreased the force of contraction (FC) in 
isolated hearts. Although RR interval was not 
significantly changed by NRG, hearts were paced at 
200-ms stimulus interval (slightly over the 
spontaneous RR interval under control condition; 210 
± 2 ms) in order to avoid any frequency-dependent 
change in FC. At 1 µmol/L concentration, NRG had 
not significant effect on FC (4.9 ± 3 % decrease); 
however at higher concentrations, it significantly 
decreased FC (p < 0.05; 97 ± 3 % maximal decrease at 
300 µmol/L). Experimental data were fitted to a Hill 
function and the estimated IC50 for inhibition of 
contraction was 72.5 µmol/L (Hill number = 1.1). 
Compared to the reference compound nifedipine (IC50 
= 0.26 µmol/L; Hill number = 1.5), NRG was less 
potent as antagonist of cardiac contraction. The action 
of NRG on FC was reversible upon washout with 
normal Tyrode solution.  
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Figure 2 
 
Naringin potentiates KCl-induced contraction in rat aortic rings 
Contraction was induced by replacing all NaCl by KCl (140 mmol/L). ACh (10 µmol/L) was perfused together 
with KCl in order to confirm the lack of endothelium activity. Upon washout of ACh, NRG (30 µmol/L) was 
perfused. As can be seen, naringin (NRG) rapidly potentiated KCl-induced contraction but only transiently. 
Application of ACh after NRG washout, corroborated that no functional endothelium was present. 
 
Effects on aortic contraction. 
To our surprise, NRG increased the force of 
contraction of rat aortic rings pre-contracted with 
isotonic KCl. The effect was transient in some 
preparations at the highest concentrations (e. g. Figure 
2). Table 1 shows the action of different concentrations 
of NRG on KCl-induced contraction; the values 
represent the maximal (peak) effect of NRG as percent 
increase over the effect of KCl. As can be seen in 
Table 1, the effect of NRG was statistically significant 
(p < 0.05) at 10 µmol/L concentration but 
physiological relevant increases (~20%) were only 
obtained at 30 and 100 µmol/L concentrations. On the 
other hand nifedipine, a classic vasodilator, exerted, as 
expected, a concentration-dependent depression of 
KCl-induced contraction of aortic rings with an IC50 of 
10.1 nmol/L (Hill number = 0.6). NRG also increased 
contraction in aortic rings pre-contracted by 
phenylephrine (PE; 10 µmol/L), however, the effect 
was statistically significant only at 30 and 100 µmol/L 
(10.5 ± 2% and 11.3 ± 2%, respectively, of maximal 
PE-induced contraction; n = 5). The action of NRG on 
the PE-induced contraction was less marked than on 
KCl-induced contraction. This could be related to the 
fact that KCl-induced contraction was less potent than 
PE-induced contraction in our conditions (99.7 ± 17 % 
vs 360.0 ± 196.0 %). More strikingly, NRG was able 
to contract aortic rings in basal conditions (not 
depolarized by isotonic KCl), an effect that was 
statistically significant only at 30 and 100 µmol/L 
concentrations (Table 1) and also in a transient 
manner. Figure 3 shows an example of this effect of 
NRG. It is to note that for the same concentrations, the 
effects of NRG on contraction were more ample in 
aortic rings in basal conditions than in KCl- (Table 1) 
or PE-contracted ones. 
In some experiments Ca
2+
 release through 
ryanodine receptors (RyR) in the sarcoplasmic 
reticulum, was blocked using ryanodine (RYA; 30 
µmol/L). Aortic rings were let to stabilize for at least 5 
min in normal Tyrode solution with 30 µmol/L RYA 
and then, they were perfused with the same Tyrode (+ 
RYA) but adding 30 µmol/L NRG. In contrast to what 
we described above, in three experiments NRG (30 
µmol/L) did not induce contraction of the aortic rings 
in basal conditions. In each case PE (10 µmol/L) 
triggered a strong contraction when it was applied 
after washout of RYA. Figure 4 shows a typical 
experiment. 
   
 
 
Lopez-Medina et al. Cardiovascular actions of naringin 
 
 
Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas/244 
 
Table 1 
Effects of NRG on aortic ring contractions 
Condition 
NRG concentration (µmol/L) 
1 3 10 30 100 
KCl-induced contraction 1.3 ± 0.9 3.6 ± 1.8 10.0 ± 3.2 * 22.4 ± 2.6 * 20.6 ± 1.0 * 
Basal 9.9 ± 8 10.4 ± 4.5 25.7 ± 5.7 * 49.8 ± 6.5 * 53.5 ± 13.5 * 
 
Values represent the maximal (peak) effect of NRG as percent increase over the effect of KCl or basal 
(resting tension). * p < 0.05 with respect to control; n ≥ 5 for each condition. 
 
Figure 3 
 
Naringin is able to contract aortic rings in basal conditions 
The preparation was stabilized with normal Tyrode solution (not shown here; see Methods) and naringin 
(NRG) was applied at increasing concentrations. Low concentrations (1 and 3 µmol/L) were without any 
significant effect on resting passive force but a clear increase in force was evident at 10 and 30 µmol/L 
concentrations. NRG was washed out by perfusing the preparation with Tyrode solution. Phenylephrine (PE; 
10 µmol/L) was then applied to confirm that the ring could elicit a strong contraction. After washout of PE, 
NRG was again applied but at a concentration of 100 µmol/L. The inset shows, in expanded scales, the effect 
of 100 µmol/L NRG. Note the huge increase in force by NRG in this preparation. 
 
DISCUSSION 
The major conclusion of this paper is that naringin 
(NRG) has direct effects on cardiac and vascular 
smooth muscles. A clear negative inotropic effect 
could be demonstrated in isolated hearts. The negative 
effect on cardiac contraction was, however, less 
important than that of the classic “Ca-antagonist” 
nifedipine and not accompanied by changes in the 
surface electrogram or heart rate. Strikingly NRG, at 
the same concentrations that it exerted a negative 
inotropic action in heart, increased the vasomotor tone 
of aortic rings precontracted with either isotonic KCl 
or phenylephrine (PE). This vasoconstrictor action of 
NRG was also manifested in resting aortic rings. 
 As stated above, minor effects on electrical 
activity accompanied the concentration-dependent 
negative inotropic action of NRG in cardiac muscle. A 
small, not statistically significant, shortening of QTc 
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was seen only at the highest concentrations. This could 
suggest that NRG had no (or a minor) effect on ionic 
channels controlling cardiac automaticity, conduction 
and repolarization. However, it should be also 
considered that it could exert multiple actions on 
different ionic channels that counterbalance to each 
other, resulting in an “apparent” absence of effects on 
cardiac surface electrogram. This is an essential issue 
that deserves further investigation since information 
about the actions of NRG on ionic channels is 
extremely limited. There are two reports showing that 
NRG is an agonist of inward rectifiers (including 
cardiac), expressed in Xenopus oocytes (Yow et al., 
2011) and in HAC15 cells (Oki et al., 2012). In 
addition, Saponara et al. (2006) showed that NRG 
(and naringenin) is a BK(Ca) agonist but with a poor 
vasorelaxing action. On the other hand, naringenin, the 
aglycone of NRG, inhibits the cardiac hERG channels 
(Scholz et al., 2005; Zitron et al., 2005). In the 
absence of information on this issue, we can only 
speculate that the negative inotropic effect of NRG 
could be due to a Ca
2+
 channel blocking action of this 
molecule. Nevertheless, effects of NRG on Na
+
 
channels and/or on the Na-Ca exchanger cannot be 
excluded. We might discard a priori a blocking effect 
of NRG on the sarcoplasmic reticulum Ca
2+
 channel 
(“ryanodine receptor”, RyR) as a cause of the negative 
inotropic action. We obtained evidence suggesting that 
NRG could act as an agonist of RyR channels (see 
below).  
 
 
Figure 4 
 
 
Naringin is not able to contract aortic rings perfused with ryanodine 
The preparation was stabilized (not shown) and then it was perfused with normal Tyrode solution plus 
ryanodine (RYA; 30 µmol/L) for at least 5 min. After this period, NRG (10 µmol/L) was applied (always in 
the presence of RYA) for ~ 3 min. No contraction was elicited by NRG in this condition. RYA and NRG were 
washed out and phenylephrine (PE; 10 µmol/L) was applied evoking a strong contraction. 
 
One striking property of NRG is that in our 
experimental conditions, it could increase the 
vasomotor tone in both resting and precontracted 
aortic rings. According to the published evidences, we 
might discard any hypothesis involving K
+
 channels 
(e.g. BK(Ca)) in the smooth muscle cell sarcolemma, 
since NRG, in any case, is a BK(Ca) opener (Saponara 
et al., 2006). It is interesting to stress here that 
Saponara et al., showed that NRG exhibited the same 
potency as naringenin over BK(Ca) channels, but it had 
a poor vasorelaxing action in aortic rings contracted by 
20 mmol/L KCl. NRG was devoid of a vasorelaxing 
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effect when KCl was 60 mmol/L. Our experiments 
with 140 mmol/L KCl uncovered an unusual 
vasomotor action for NRG. 
When aortic ring contraction was induced by 
PE, the effects of NRG were less ample than with 
isotonic KCl, a result that could be related to the 
amount of Ca
2+
 release in each case. This suggests that 
the effect of NRG is limited by the amount of Ca
2+
 
previously released. According to the strength 
developed in each case (see Results), it could be 
possible that PE-induced Ca
2+
 release was greater than 
with KCl and then, less Ca
2+
 could be additionally 
released by NRG. Two lines of evidence suggest that 
this might be the case. First, the greatest NRG-induced 
contractions were observed in basal (resting) aortic 
rings (see Table 1) where Ca
2+
 release mechanisms are 
not operating. Second, when aortic rings were 
perfused with ryanodine (RYA), a well-known RyR 
blocker, NRG was not able to induce contraction. In 
our experimental conditions (long exposure to 30 
µmol/L RYA), RYA is known to fully block the RyR 
(Pessah and Zimanyi, 1991; Ostrovskaya et al., 2007). 
Summarizing, although further research is obviously 
needed, the present results suggest that NRG could act 
as a sarcoplasmic Ca
2+
 release channel (RyR) agonist 
and have as targets several voltage-dependent ionic 
channels. 
Naringin is an active ingredient identified in 
citrus fruits, a major source of dietetic flavonoids. As 
stated in Introduction, there is a longstanding interest 
on these compounds not only as dietetic supplements 
but also as possible therapeutic agents for the 
treatment of several human diseases. It is thus of 
interest to study the pharmacological properties of 
these compounds and to identify not only their 
beneficial profiles but also their potential undesirable 
side effects. In this sense the present results show that 
NRG could have a negative inotropic action in heart 
and a potential vasoconstrictor action (aorta). Whether 
these effects are relevant or not to human health 
requires further investigation since NRG is in part 
metabolized to naringenin by enteral bacteria that play 
an important role in this metabolic pathway. 
Nonetheless, the fate of NRG not metabolized 
intraluminally to naringenin is not clear. Naringin 
could be also transformed to naringenin by gut wall or 
hepatic enzymes but this remains to be examined 
(Fuhr and Kummert, 1995). 
 
CONCLUSION 
We may conclude that NRG has direct actions on 
cardiac and smooth muscles that should be taken into 
account when considering this molecule either as a 
dietetic supplement or as a template to develop 
therapeutic agents for human diseases. 
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